Ovarian Cancer
Protocol Code: D8991C00001, IND number: 174954Protocol Title: A Randomised, Open label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα low Expressing High grade Platinum resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01).
- Details
ClinicalTrials.gov ID:
NCT07218809
Diagnosis Type:
NA
USOR Number:
- Address
,
P: